The treatment of Acute Lymphoblastic Leukemia (ALL) is a long-term process that requires patience from patients, their families, and the healthcare team. The primary goals of treatment are to reduce the percentage of leukemia cells (blasts) in the bone marrow, which is typically detected at over 20% at diagnosis, to below 5%, and to eradicate the microscopic tumor burden known as 'minimal residual disease'. To achieve these goals, the following approach is adopted in the treatment of Acute Lymphoblastic Leukemia (ALL):